Vectorious Medical Technologies
Miniature Implant for Left Atrial Monitoring
Company Overview
Snapshot
Founded in October 2011 by Eyal Orion, Vectorious Medical Technologies operates with 51–200 employees. The company raised $19.5M across 4 funding rounds from 11 investors. In September 2025, Vectorious Medical Technologies was acquired by Edwards Lifesciences.
Business overview
Vectorious Medical Technologies develops an in-heart microcomputer designed to monitor the left atrial pressure, providing optimal treatment for heart disease patients. Its core product, the V-LAP sensory implant, is a digital, wireless, and battery-less device that delivers high-resolution waveform morphology from within the heart. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, serving patients and healthcare providers globally.
Strategic signal
In September 2025, Vectorious Medical Technologies was acquired by Edwards Lifesciences. This acquisition highlights the strategic value of Vectorious's V-LAP technology in the cardiovascular medical device market and signals a significant exit for investors, validating the company's innovative approach to heart disease management.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant corporate development for Vectorious Medical Technologies?
- Vectorious Medical Technologies was acquired by Edwards Lifesciences for $497 million in September 2025.
- What is the primary technology developed by Vectorious Medical Technologies?
- Vectorious Medical Technologies has developed the V-LAP sensory implant, an in-heart microcomputer that monitors the heart's left atrium pressure to optimize treatment for heart disease patients.
- When did Vectorious Medical Technologies receive a breakthrough device designation?
- In November 2020, Vectorious Medical Technologies was granted a breakthrough device designation for its left atrial pressure monitoring device.
- What was a key finding from the VECTOR-HF I study?
- In May 2022, Vectorious announced that the VECTOR-HF I study confirmed the safety and accuracy of its V-LAP In-Heart Sensor for left atrial pressure management of heart failure.